Session

What is new in GORD management: Drugs or surgery?

NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE AND RISK OF ESOPHAGEAL ADENOCARCINOMA
NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE AND RISK OF ESOPHAGEAL ADENOCARCINOMA

What is new in GORD management: Drugs or surgery?  et al.

LINAPRAZAN GLURATE IS WELL TOLERATED IN THE TREATMENT OF PATIENTS WITH EROSIVE ESOPHAGITIS: A DOUBLE-BLIND, RANDOMIZED, DOSE FINDING STUDY
LINAPRAZAN GLURATE IS WELL TOLERATED IN THE TREATMENT OF PATIENTS WITH EROSIVE ESOPHAGITIS: A DOUBLE-BLIND, RANDOMIZED, DOSE FINDING STUDY

What is new in GORD management: Drugs or surgery?  et al.

RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ZASTAPRAZAN COMPARED WITH ESOMEPRAZOLE IN EROSIVE OESOPHAGITIS [ZASTAPRAZAN EROSIVE REFLUX OESOPHAGITIS-1 STUDY (ZERO-1)]
RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ZASTAPRAZAN COMPARED WITH ESOMEPRAZOLE IN EROSIVE OESOPHAGITIS [ZASTAPRAZAN EROSIVE REFLUX OESOPHAGITIS-1 STUDY (ZERO-1)]

What is new in GORD management: Drugs or surgery?  et al.

ANTIREFLUX SURGERY VERSUS ANTIREFLUX MEDICATION AND RISK OF ESOPHAGEAL ADENOCARCINOMA IN PATIENTS WITH BARRETT’S ESOPHAGUS
ANTIREFLUX SURGERY VERSUS ANTIREFLUX MEDICATION AND RISK OF ESOPHAGEAL ADENOCARCINOMA IN PATIENTS WITH BARRETT’S ESOPHAGUS

What is new in GORD management: Drugs or surgery?  et al.

BEVACIZUMAB-800CW FLUORESCENCE MOLECULAR ENDOSCOPY IMPROVES EARLY CANCER DETECTION AND STANDARDIZATION IN BARRETT’S ESOPHAGUS SURVEILLANCE
BEVACIZUMAB-800CW FLUORESCENCE MOLECULAR ENDOSCOPY IMPROVES EARLY CANCER DETECTION AND STANDARDIZATION IN BARRETT’S ESOPHAGUS SURVEILLANCE

What is new in GORD management: Drugs or surgery?  et al.

BEVACIZUMAB-800CW FLUORESCENCE MOLECULAR ENDOSCOPY IMPROVES EARLY CANCER DETECTION AND STANDARDIZATION IN BARRETT’S ESOPHAGUS SURVEILLANCE
BEVACIZUMAB-800CW FLUORESCENCE MOLECULAR ENDOSCOPY IMPROVES EARLY CANCER DETECTION AND STANDARDIZATION IN BARRETT’S ESOPHAGUS SURVEILLANCE

RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ZASTAPRAZAN COMPARED WITH ESOMEPRAZOLE IN EROSIVE OESOPHAGITIS [ZASTAPRAZAN EROSIVE REFLUX OESOPHAGITIS-1 STUDY (ZERO-1)]
RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ZASTAPRAZAN COMPARED WITH ESOMEPRAZOLE IN EROSIVE OESOPHAGITIS [ZASTAPRAZAN EROSIVE REFLUX OESOPHAGITIS-1 STUDY (ZERO-1)]

LINAPRAZAN GLURATE IS WELL TOLERATED IN THE TREATMENT OF PATIENTS WITH EROSIVE ESOPHAGITIS: A DOUBLE-BLIND, RANDOMIZED, DOSE FINDING STUDY
LINAPRAZAN GLURATE IS WELL TOLERATED IN THE TREATMENT OF PATIENTS WITH EROSIVE ESOPHAGITIS: A DOUBLE-BLIND, RANDOMIZED, DOSE FINDING STUDY

NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE AND RISK OF ESOPHAGEAL ADENOCARCINOMA
NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE AND RISK OF ESOPHAGEAL ADENOCARCINOMA

ANTIREFLUX SURGERY VERSUS ANTIREFLUX MEDICATION AND RISK OF ESOPHAGEAL ADENOCARCINOMA IN PATIENTS WITH BARRETT’S ESOPHAGUS
ANTIREFLUX SURGERY VERSUS ANTIREFLUX MEDICATION AND RISK OF ESOPHAGEAL ADENOCARCINOMA IN PATIENTS WITH BARRETT’S ESOPHAGUS

Item 1 - 10 / 10
1